K C B Tan1,2, W S Chow3, A W K Tso3, A Xu3,4, H F Tse3,4, R L C Hoo3, D J Betteridge5, K S L Lam3,4. 1. Department of Medicine, University of Hong Kong, Queen Mary Hospital, Pokfulam Road, Hong Kong SAR, People's Republic of China. kcbtan@hkucc.hku.hk. 2. Research Centre of Heart, Brain, Hormone and Healthy Aging, University of Hong Kong, Hong Kong SAR, People's Republic of China. kcbtan@hkucc.hku.hk. 3. Department of Medicine, University of Hong Kong, Queen Mary Hospital, Pokfulam Road, Hong Kong SAR, People's Republic of China. 4. Research Centre of Heart, Brain, Hormone and Healthy Aging, University of Hong Kong, Hong Kong SAR, People's Republic of China. 5. Department of Medicine, Royal Free and University College London Medical School, London, UK.
Abstract
AIMS/HYPOTHESIS: Interfering with the activation of receptor for AGE (RAGE) by using a soluble form of the AGE receptor (sRAGE) prevents or ameliorates the vascular complications of diabetes in experimental studies. Relatively little is known about factors that influence endogenous circulating sRAGE in humans. We investigated the impact of improving glycaemic control on serum total sRAGE and endogenous secretory RAGE (esRAGE), a splice variant of sRAGE, and compared the effect of rosiglitazone with that of sulfonylurea. METHODS: A randomised, open-label, parallel group study was performed with 64 participants randomised to receive add-on therapy with eitherrosiglitazone or sulfonylurea. Serum total sRAGE andesRAGE and metabolic parameters were measured before and after 6 months of treatment. RESULTS: At 6 months, both rosiglitazone and sulfonylurea resulted in a significant reduction in HbA(1c), fasting glucose and AGE. However, significant increases in total sRAGE and esRAGE were only seen in the rosiglitazone group. As a result, serum esRAGE was higher in the rosiglitazone group than in the sulfonylurea group at 6 months (p < 0.01), whereas the differences in sRAGE between the two groups did not reach statistical significance. Stepwise linear regression analysis showed that treatment modality made a greater contribution than the changes in HbA(1c) to the subsequent changes in esRAGE levels at 6 months. CONCLUSIONS/ INTERPRETATION:Treating type 2 diabetic patients withthiazolidinedione can increase circulating levels of esRAGE and sRAGE. Whether modulation of circulating sRAGE has a beneficial effect on diabetic complications will have to be evaluated in long-term prospective studies.
RCT Entities:
AIMS/HYPOTHESIS: Interfering with the activation of receptor for AGE (RAGE) by using a soluble form of the AGE receptor (sRAGE) prevents or ameliorates the vascular complications of diabetes in experimental studies. Relatively little is known about factors that influence endogenous circulating sRAGE in humans. We investigated the impact of improving glycaemic control on serum total sRAGE and endogenous secretory RAGE (esRAGE), a splice variant of sRAGE, and compared the effect of rosiglitazone with that of sulfonylurea. METHODS: A randomised, open-label, parallel group study was performed with 64 participants randomised to receive add-on therapy with either rosiglitazone or sulfonylurea. Serum total sRAGE and esRAGE and metabolic parameters were measured before and after 6 months of treatment. RESULTS: At 6 months, both rosiglitazone and sulfonylurea resulted in a significant reduction in HbA(1c), fasting glucose and AGE. However, significant increases in total sRAGE and esRAGE were only seen in the rosiglitazone group. As a result, serum esRAGE was higher in the rosiglitazone group than in the sulfonylurea group at 6 months (p < 0.01), whereas the differences in sRAGE between the two groups did not reach statistical significance. Stepwise linear regression analysis showed that treatment modality made a greater contribution than the changes in HbA(1c) to the subsequent changes in esRAGE levels at 6 months. CONCLUSIONS/ INTERPRETATION: Treating type 2 diabeticpatients with thiazolidinedione can increase circulating levels of esRAGE and sRAGE. Whether modulation of circulating sRAGE has a beneficial effect on diabetic complications will have to be evaluated in long-term prospective studies.
Authors: In Ho Park; Soo In Yeon; Ju Ho Youn; Ji Eun Choi; Nobuyuki Sasaki; In-Hong Choi; Jeon-Soo Shin Journal: Mol Immunol Date: 2004-03 Impact factor: 4.407
Authors: Kathryn C B Tan; Wing-Sun Chow; Victor H G Ai; Christine Metz; Richard Bucala; Karen S L Lam Journal: Diabetes Care Date: 2002-06 Impact factor: 19.112
Authors: M T Goova; J Li; T Kislinger; W Qu; Y Lu; L G Bucciarelli; S Nowygrod; B M Wolf; X Caliste; S F Yan; D M Stern; A M Schmidt Journal: Am J Pathol Date: 2001-08 Impact factor: 4.307
Authors: Lana E Hanford; Jan J Enghild; Zuzana Valnickova; Steen V Petersen; Lisa M Schaefer; Todd M Schaefer; Todd A Reinhart; Tim D Oury Journal: J Biol Chem Date: 2004-09-20 Impact factor: 5.157
Authors: Andréa E M Stinghen; Ziad A Massy; Helen Vlassara; Gary E Striker; Agnès Boullier Journal: J Am Soc Nephrol Date: 2015-08-26 Impact factor: 10.121
Authors: Anastasia Z Kalea; Fiona See; Evis Harja; Maria Arriero; Ann Marie Schmidt; Barry I Hudson Journal: Cancer Res Date: 2010-06-22 Impact factor: 12.701
Authors: Mahmoud Al Rifai; Andrea L C Schneider; Alvaro Alonso; Nisa Maruthur; Christina M Parrinello; Brad C Astor; Ron C Hoogeveen; Elsayed Z Soliman; Lin Y Chen; Christie M Ballantyne; Marc K Halushka; Elizabeth Selvin Journal: J Diabetes Complications Date: 2014-11-25 Impact factor: 2.852